stoxline Quote Chart Rank Option Currency Glossary
  
Astria Therapeutics, Inc. (ATXS)
8.79  -0.04 (-0.45%)    06-18 11:15
Open: 8.85
High: 8.89
Volume: 55,886
  
Pre. Close: 8.83
Low: 8.76
Market Cap: 483(M)
Technical analysis
2024-06-18 10:47:57 AM
Short term     
Mid term     
Targets 6-month :  11.07 1-year :  11.72
Resists First :  9.48 Second :  10.03
Pivot price 9.06
Supports First :  8.58 Second :  7.14
MAs MA(5) :  9.05 MA(20) :  9.06
MA(100) :  11.77 MA(250) :  9.04
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  31.8 D(3) :  43.4
RSI RSI(14): 40.1
52-week High :  16.89 Low :  4.26
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ATXS ] has closed above bottom band by 16.5%. Bollinger Bands are 79.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.19 - 9.26 9.26 - 9.32
Low: 8.48 - 8.56 8.56 - 8.61
Close: 8.72 - 8.85 8.85 - 8.93
Company Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Headline News

Tue, 18 Jun 2024
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - Defense World

Sun, 16 Jun 2024
Perceptive Advisors LLC Buys 1,814,608 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Wed, 12 Jun 2024
ADAR1 Capital Management LLC Purchases Shares of 191,251 Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Tue, 04 Jun 2024
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mon, 03 Jun 2024
53204 Shares in Astria Therapeutics, Inc. (NASDAQ:ATXS) Acquired by Trexquant Investment LP - Defense World

Fri, 24 May 2024
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 55 (M)
Shares Float 31 (M)
Held by Insiders 0.4 (%)
Held by Institutions 105.1 (%)
Shares Short 4,180 (K)
Shares Short P.Month 5,050 (K)
Stock Financials
EPS -2.41
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.96
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -16.5 %
Return on Equity (ttm) -28.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -74 (M)
Levered Free Cash Flow -39 (M)
Stock Valuations
PE Ratio -3.68
PEG Ratio 0
Price to Book value 1.77
Price to Sales 0
Price to Cash Flow -6.52
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android